J
Jun Chen
Researcher at Shanghai Jiao Tong University
Publications - 2300
Citations - 100809
Jun Chen is an academic researcher from Shanghai Jiao Tong University. The author has contributed to research in topics: Medicine & Chemistry. The author has an hindex of 136, co-authored 1856 publications receiving 77368 citations. Previous affiliations of Jun Chen include Peking Union Medical College & Nankai University.
Papers
More filters
Journal ArticleDOI
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers,Joel D. Leverson,Erwin R. Boghaert,Scott L. Ackler,Nathaniel D. Catron,Jun Chen,Brian D. Dayton,Hong Ding,Sari H. Enschede,Wayne J. Fairbrother,David C.S. Huang,David C.S. Huang,Sarah G. Hymowitz,Sha Jin,Seong Lin Khaw,Seong Lin Khaw,Peter Kovar,Lloyd T. Lam,Jackie Lee,Heather Maecker,Kennan C. Marsh,Kylie D. Mason,Kylie D. Mason,Kylie D. Mason,Michael J. Mitten,Paul Nimmer,Anatol Oleksijew,Chang H. Park,Cheol-Min Park,Cheol-Min Park,Darren C. Phillips,Andrew W. Roberts,Andrew W. Roberts,Andrew W. Roberts,Deepak Sampath,John F. Seymour,John F. Seymour,Morey L. Smith,Gerard M. Sullivan,Stephen K. Tahir,Chris Tse,Michael D. Wendt,Yu Xiao,John Xue,Haichao Zhang,Rod A. Humerickhouse,Saul H. Rosenberg,Steven W. Elmore +47 more
TL;DR: The re-engineering of navitoclax is reported to create a highly potent, orally bioavailable and BCL-2–selective inhibitor, ABT-199, which inhibits the growth of BCL–dependent tumors in vivo and spares human platelets, indicating that selective pharmacological inhibition of Bcl-2 shows promise for the treatment of B CL-2-dependent hematological cancers.
Journal ArticleDOI
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Christin Tse,Alexander R. Shoemaker,Jessica Adickes,Mark G. Anderson,Jun Chen,Sha Jin,Eric F. Johnson,Kennan C. Marsh,Michael J. Mitten,Paul Nimmer,Lisa R. Roberts,Stephen K. Tahir,Yu Xiao,Xiufen Yang,Haichao Zhang,Stephen W. Fesik,Saul H. Rosenberg,Steven W. Elmore +17 more
TL;DR: The biological properties and rationale for clinical trials evaluating ABT-263 in small-cell lung cancer and B-cell malignancies are provided and the oral efficacy should provide dosing flexibility to maximize clinical utility both as a single agent and in combination regimens are reported.
Journal ArticleDOI
α‐Fe2O3 Nanotubes in Gas Sensor and Lithium‐Ion Battery Applications
Journal ArticleDOI
The mental health of medical workers in Wuhan, China dealing with the 2019 novel coronavirus.
Lijun Kang,Yi Li,Shaohua Hu,Min Chen,Can Yang,Bing Xiang Yang,Ying Wang,Jianbo Hu,Jianbo Lai,Xiancang Ma,Jun Chen,Lili Guan,Gaohua Wang,Hong Ma,Zhongchun Liu +14 more
TL;DR: The present work provides a rationale based approach for the selection of drugs with potential antiviral activity for SARS-CoV-2 infection better than the investigational drug/divdivRemdesivir and other antiviral drugs/drug combinations being evaluated.
Journal ArticleDOI
Co3O4 nanomaterials in lithium-ion batteries and gas sensors
Wei-Yang Li,Li-Na Xu,Jun Chen +2 more
TL;DR: In this paper, a porous-alumina-template method was used to obtain high discharge capacity and superior cycling reversibility of Co3O4 nanotubes, which exhibited excellent sensitivity to hydrogen and alcohol, owing to their hollow, nanostructured character.